Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 2.2% – Time to Sell?

Zomedica Corp. (NYSEAMERICAN:ZOM)’s share price traded down 2.2% during mid-day trading on Thursday . The company traded as low as $0.13 and last traded at $0.14. 8,794,663 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 16,965,762 shares. The stock had previously closed at $0.14.

Analyst Ratings Changes

Separately, Noble Financial raised shares of Zomedica to a “strong-buy” rating in a report on Monday, November 11th.

Zomedica Trading Down 5.2 %

The firm has a market capitalization of $128.37 million, a PE ratio of -2.18 and a beta of 1.04.

Institutional Investors Weigh In On Zomedica

A hedge fund recently raised its stake in Zomedica stock. Geode Capital Management LLC boosted its holdings in shares of Zomedica Corp. (NYSEAMERICAN:ZOM) by 3.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,929,716 shares of the company’s stock after acquiring an additional 321,395 shares during the period. Geode Capital Management LLC owned 1.01% of Zomedica worth $1,363,000 at the end of the most recent reporting period. 8.95% of the stock is currently owned by institutional investors.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.